Eisai Co ((JP:4523)) has held its Q4 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eisai’s latest earnings call struck an overall upbeat tone, as strong performances from its key global brands and the rapid international rollout of Alzheimer’s drug LEQEMBI powered solid revenue growth. Management, however, balanced this optimism with caution on rising costs, slower-than-planned U.S. uptake, and the emerging threat of rival therapies in a fast-evolving market.
Global Brands Drive Double-Digit Growth
Three global products, LENVIMA, Lemborexant, and LEQEMBI, generated ¥426.5 billion in revenue, marking a robust 24% year-on-year increase that underscored Eisai’s reliance on its flagship portfolio. This performance positioned the company’s branded franchise as the primary growth engine and highlighted the commercial strength of its oncology and neurology offerings.
LEQEMBI’s Expanding International Footprint
LEQEMBI continued its rapid global rollout, securing approvals in 44 countries and undergoing regulatory review in another 12, signaling broad international acceptance of the Alzheimer’s therapy. This expansion not only diversifies Eisai’s geographic revenue base but also sets the stage for stronger long-term growth as launches progress.
Revenue Beats Forecasts
Total revenue climbed to ¥789.4 billion, a 6% increase from the previous year that exceeded management’s own projections and underscored effective execution across key franchises. The beat suggests Eisai is successfully translating its pipeline and portfolio into top-line momentum despite pricing and competitive pressures.
LEQEMBI Revenue Outpaces Expectations
Global LEQEMBI revenue reached ¥44.3 billion for fiscal 2024, surpassing the company’s full-year forecast and reinforcing the drug’s status as a critical future driver. This outperformance reflects growing physician adoption and payer access, even as the product remains in the early stages of its commercial life cycle.
LENVIMA Sustains Double-Digit Expansion
LENVIMA delivered more than ¥328 billion in global revenue, with the Americas posting a strong 28% year-on-year increase that highlighted the therapy’s resilience in a competitive oncology market. The sustained double-digit growth underscores LENVIMA’s role as a cornerstone asset and key cash generator for Eisai.
Rising Cost of Sales Pressures Margins
Cost of sales rose by 1.7 percentage points, driven by Inflation Reduction Act related expenses for LENVIMA and adverse product mix effects that weighed on profitability. These pressures highlight a growing regulatory and pricing headwind that investors will watch closely as Eisai seeks to defend margins.
Slower U.S. LEQEMBI Penetration
LEQEMBI’s U.S. uptake lagged internal expectations, with management describing the market as only nearing the end of the demand stimulation phase rather than broad expansion. This slower penetration suggests logistical, reimbursement, or awareness hurdles that could delay the full revenue ramp in the company’s largest market.
Heavy Investment in LEQEMBI Weighs on Profit
High R&D and SG&A spending tied to LEQEMBI dampened operating profit, reflecting substantial investment in clinical, launch, and commercialization activities. Eisai noted that R&D expenses for LEQEMBI are expected to decline, indicating some relief ahead even as marketing support remains elevated.
Management Downplays Competitive Threats
Investors queried the potential impact of competing products such as Cassella, but management downplayed the immediate threat, emphasizing LEQEMBI’s clinical profile and early mover advantage. While competition in Alzheimer’s treatments is intensifying, Eisai signaled confidence in its positioning and strategy.
Forward Guidance Points to Stronger LEQEMBI Growth
Looking ahead to fiscal 2025, Eisai forecasts LEQEMBI’s global revenue to rise to ¥76.5 billion, with the U.S. and Japan entering a demand expansion phase that should meaningfully boost sales. The company also plans European launches, including Germany and Austria, while maintaining tighter control of R&D and SG&A ratios after exceeding revenue and profit forecasts in fiscal 2024.
Eisai’s earnings call painted a picture of a company successfully leveraging its global brands to outpace expectations while navigating rising costs and a challenging U.S. launch environment for LEQEMBI. For investors, the key takeaways are solid top-line growth, strong momentum in core products, and a clear bet that LEQEMBI’s global expansion will offset near-term margin pressure and competitive noise.